| Bioactivity | Anecortave (AL-4940) is an angiogenesis inhibitor. Anecortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors[1][2]. |
| Name | Anecortave |
| CAS | 10184-70-0 |
| Formula | C21H28O4 |
| Molar Mass | 344.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kaiser PK, et al. Posterior juxtascleral depot administration of anecortave acetate. Surv Ophthalmol. 2007 Jan;52 Suppl 1:S62-9. [2]. Jockovich ME, et al. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1264-8. |